1. Xu JY#, Xiong YY, Tang RJ, Jiang WY, Ning Y, Gong ZT, Huang PS, Chen GH, Xu J, Wu CX, Hu MJ, Xu J, Xu Y, Huang CR, Jin C, Lu XT, Qian HY, Li XD, Yang YJ*. Interleukin-5-induced eosinophil population improves cardiac function after myocardial infarction. Cardiovasc Res. 2022 Jul 20;118(9):2165-2178. (IF=13.081)
2.Xiong Y#, Tang R, Xu J, Jiang W, Gong Z, Zhang L, Ning Y, Huang P, Xu J, Chen G, Li X, Hu M, Xu J, Wu C, Jin C, Li X, Qian H, Yang Y*. Tongxinluo-pretreated mesenchymal stem cells facilitate cardiac repair via exosomal transfer of miR-146a-5p targeting IRAK1/NF-κB p65 pathway. Stem Cell Res Ther. 2022 Jul 7;13(1):289. (IF=8.096)
3. Cui K#, Fu R#, Yang J, Xu H, Yin D, Song W, Wang H, Zhu C, Feng L, Wang Z, Wang Q, Lu Y, Dou K*, Yang Y*. Admission Blood Glucose and 2-Year Mortality After Acute Myocardial Infarction in Patients With Different Glucose Metabolism Status: A Prospective, Nationwide, and Multicenter Registry. Front Endocrinol (Lausanne). 2022 Jun 15;13:898384. (IF=6.055)
4. Huang P#, Wang L, Li Q, Tian X, Xu J, Xu J, Xiong Y, Chen G, Qian H, Jin C, Yu Y, Cheng K, Qian L*, Yang Y*. Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19. Cardiovasc Res. 2020 Feb 1;116(2):353-367. (IF=13.081)
5.Xu H#, Yang Y*, Wang C, Yang J,Li W, Zhang X, Ye Y, Dong Q, Fu R, Sun H, Yan X,Gao X, Wang Y, Jia X, Sun Y, Wu Y, Zhang J, Zhao W, Sabatine MS, Wiviott SD, for CAMI registry investigators. Association of hospital-level differences in care with outcomes among patients with acute ST-Segment elevation myocardial infarction in China. JAMA Network open. 2020;3(10):e2021677. (IF=11.64)
6.Chen G#, Xu C, Gillette TG, Huang T, Huang P, Li Q, Li X, Li Q, Ning Y, Tang R, Huang C, Xiong Y, Tian X, Xu J, Xu J, Chang L, Wei C, Jin C, Hill JA*, Yang Y*. Cardiomyocyte-derived small extracellular vesicles can signal eNOS activation in cardiac microvascular endothelial cells to protect against Ischemia/Reperfusion injury. Theranostics. 2020 Sep 23;10(25):11754-11774. (IF=11.600)
7. Xu J#, Xiong YY, Li Q, Hu MJ, Huang PS, Xu JY, Tian XQ, Jin C, Liu JD, Qian L*, Yang YJ*. Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction. Stem Cells Transl Med. 2019 Oct;8(10):1068-1083. (IF=7.655)
8.Xu B#, Redfors B*, Yang Y*, Qiao S, Wu Y, Chen J, Liu H, Chen J, Xu L, Zhao Y, Guan C, Gao R, Généreux P. Impact of Operator Experience and Volume on Outcomes After Left Main Coronary Artery Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2016 Oct 24;9(20):2086-2093. (IF=11.075)
9. Yang YJ#*, Kandzari DE, Gao Z, Xu B, Chen JL, Qiao SB, Li JJ, Qin XW, Yao M, Wu YJ, Yuan JQ, Chen J, Liu HB, Dai J, Chen T, Wang Y, Li W, Gao RL. Transradial versus transfemoral method of percutaneous coronary revascularization for unprotected left main coronary artery disease: comparison of procedural and late-term outcomes. JACC Cardiovasc Interv. 2010 Oct;3(10):1035-42. (IF=11.075)
10. Yang YJ#*, Qian HY, Huang J, Geng YJ, Gao RL, Dou KF, Yang GS, Li JJ, Shen R, He ZX, Lu MJ, Zhao SH. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J. 2008 Jun;29(12):1578-90. (IF=35.855)